ReviewEmerging infectious diseases2008
Rise and persistence of global M1T1 clone of Streptococcus pyogenes.
Review in Emerging infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 184 citations in OpenAlex.
- Dynamic tethering of M protein drives pathological inflammation during group A Streptococcus infections.PLoS pathogens · 2026Article
- Emergence of distinct Streptococcus pyogenes emm1 and emm12 lineages in China.Nature microbiology · 2026Article
- Acquisition of toxin-encoding lysogenic bacteriophage elements enhances the virulence of pandemicInfection and immunity · 2026Article
- M1 protein from group ABlood vessels, thrombosis & hemostasis · 2025Article
- Article
- A Rapid Molecular Detection Tool for Toxigenic M1UK Streptococcus pyogenes.The Journal of infectious diseases · 2025Article
- Characterization of a novelmBio · 2025Article
- An efficientmBio · 2024Article
- EmergentInfection and immunity · 2024Article
- Outbreak ofMicrobiology spectrum · 2024Article
- The overlooked bacterial pandemic.Seminars in immunopathology · 2024Review
- Concurrent Brain Subregion Microgliosis in an HLA-II Mouse Model of Group A Streptococcal Skin Infection.Microorganisms · 2023Article
- Detection of Streptococcus pyogenes M1Nature communications · 2023Article
- PERK Pathway Inhibitors Cure Group A Streptococcal Necrotizing Fasciitis in a Murine Model.Bio-protocol · 2022Article
- The group AInfectious microbes & diseases · 2022Article
- Loss ofMicroorganisms · 2022Article
- The exploitation of human glycans by Group A Streptococcus.FEMS microbiology reviews · 2022Article
- Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2022Article
- Host-to-Host Group A Streptococcus Transmission Causes Infection of the Lamina Propria but Not Epithelium of the Upper Respiratory Tract in MyD88-Deficient Mice.Infection and immunity · 2022Article
- Streptococcal superantigens and the return of scarlet fever.PLoS pathogens · 2021Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resurgence of severe invasive group A streptococcal infections in the 1980s is a typical example of the reemergence of an infectious disease. We found that this resurgence is a consequence of the diversification of particular strains of the bacteria. Among these strains is a highly virulent subclone of serotype M1T1 that has exhibited unusual epidemiologic features and virulence, unlike all other streptococcal strains. This clonal strain, commonly isolated from both noninvasive and invasive infection cases, is most frequently associated with severe invasive diseases. Because of its unusual prevalence, global spread, and increased virulence, we investigated the unique features that likely confer its unusual properties. In doing so, we found that the increased virulence of this clonal strain can be attributed to its diversification through phage mobilization and its ability to sense and adapt to different host environments; accordingly, the fittest members of this diverse bacterial community are selected to survive and invade host tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.